Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Other

Centaurus Biopharma Co., Ltd.

Lianyungang Runzhong Pharmaceutical Co., Ltd.

Advenchen Laboratories Nanjing Ltd

Ping Dong

Xiongxiong He

Xiquan Zhang

Hongjiang Xu

Lei Liu

Yunfu Luo

Ying Zhang

Fei Liu

Shanchun Wang

Hongmei Gu

Jiahui Cai

Rui Zhao

Wei Song

Xunqiang Wang

Zhilin Chen

Changhui Li

Xuebing Zhu

Shang Wang

Xifeng Lu

Yi Xu

Laicun Li

Jing Gao

Shan Zhou

Yuanyuan Sun

Lei Huang

Deyang Chen

Zhongying Sun

Shanshan Sui

Zhenxue Deng

Bo Jiang

Jiao Xu

Xin Huang

Yanju Cheng

Pengyue Bao

Miao Yang

Wanjing Li

Xiongfeng Ji

Zhong Xu

Hui Hui

Huanqing Zhang

Hao Zhou

A solid pharmaceutical composition containing a 1,3,5-triazine derivative or a pharmaceutically acceptable salt thereof and a preparation method therefor. In particular, involved are a solid pharmaceutical composition containing 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazine-2-amine or a pharmaceutically acceptable salt thereof and a preparation method therefor. The solid pharmaceutical composition has a good stability, a fast dissolution rate and a high bioavailability, and is suitable for clinical production and use.

Solid pharmaceutical composition containing 1,3,5-triazine derivative or salt thereof

A novel dry powder inhaler. By providing a plurality of capsule chambers () arranged in parallel in a capsule dry powder inhalation device, a medicine dispenser containing active components of a composite product or their mixture separately is provided. The dry powder inhaler has a simple structure and is convenient to operate. In addition, the parameters of air inlet channels and an air outlet channel can be adjusted by means of each capsule chamber () according to the properties of powder of a medicine or a combination, so as to provide an appropriate particle distribution for each active component.

Dry powder inhaler

The present application relates to the field of pharmaceutical technology, specifically to the crystal habit and crystalline powder preparation of quinoline derivatives, and more specifically, to the crystal habit and crystalline powder preparation of anlotinib dihydrochloride. The compound of formula II disclosed herein is a crystalline powder with a flaky crystal habit having a specific surface area &#x2265;10 m/g and a particle-size distribution of X&#x2264;50 &#x3bc;m and/or X&#x2264;500 &#x3bc;m, such that a large specific surface area is provided without reducing the particle size of the drug by a physical method under the condition of a broad particle-size distribution, and the drug can rapidly dissolving. In addition to excellent dissolution property, the crystalline powder is also beneficial to industrial manufacturing, featuring simplified process and cost-efficiency.

Crystal habit of quinoline derivative and preparation method for crystalline powder thereof

The present invention belongs to the field of medicine, relates to an inhaled preparation of isoglycyrrhizic acid or a salt thereof, and in particular relates to an inhaled preparation of magnesium isoglycyrrhizinate and the use thereof in preparing drugs for treating respiratory system diseases.

Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases

A pharmaceutical composition comprising dabigatran etexilate, and preparation method and use thereof, and solid preparation comprising the pharmaceutical composition; the pharmaceutical composition comprises a vitamin C layer and a dabigatran etexilate layer separated by a semipermeable film layer, and the semipermeable film layer comprises a water-soluble compound, a water-insoluble compound and an optional anti-sticking agent and/or plasticizer.

Pharmaceutical composition comprising dabigatran etexilate, and preparation method, solid preparation and use thereof

The present application provides a pharmaceutical composition comprising 6-(2-chloro-4-iodophenylamino)-N-(2-hydroxyethoxy)-5-methyl-4-oxo-4,5-dihydrofuro[3,2-c]pyridine-7-carboxamide or a pharmaceutically acceptable salt, a binder, a surface stabilizer and a dispersant, wherein the pharmaceutical composition can be dispersed in water to form a pharmaceutical suspension having a median particle size, X50, of 0.5 &#x3bc;m to 4.0 &#x3bc;m. Also disclosed are a preparation method thereof and the use thereof for treating cancers.

Pharmaceutical composition of MEK inhibitor and preparation method thereof

The present invention provides 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopro-pylamine used for combating a tumor. Specially, the present invention refers to method for treating tumor, pharmaceutical composition and medicinal kit related to the described compound. Administrating the compound with a suitable dosage regimen can not only make the patient's plasma concentration maintain the level of 100 ng/ml or lower, but also achieve effects of treatments and obtain benefits for various tumours.

Method for treating tumour, pharmaceutical composition and medicinal kit

Growing community of inventors

Lianyungang, China

Ping Dong